Notwithstanding market nervousness toward the end the first quarter of 2014 the period was characterized by a tsunami of cash flooding into biotech coffers. Both global public and private companies benefited. As a result, the sector collectively raised $9.5 billion – almost double the amount raised in the same period last year according to data from BioWorld Snapshots.